Keyphrases
Drug Response
100%
Type 2 Diabetes Mellitus (T2DM)
80%
Renal Risk
77%
Diabetic Kidney Disease
76%
High Cardiovascular Risk
66%
Linagliptin
66%
Confidence Interval
65%
Placebo
52%
Personalized Medicine
44%
Risk Markers
44%
Response Rate
41%
Risk Change
38%
Drug Effects
38%
End-stage Renal Disease
37%
Heart Failure Outcomes
33%
Cholesterol
33%
Trial Design
33%
Renoprotective Effect
33%
Dapagliflozin
33%
Langer
33%
Statins
33%
Marker Effects
33%
Proteinuria Reduction
33%
Renal Risk Score
33%
Patient Outcomes
33%
Biomarker Approach
33%
Outcome-based
33%
Renal Function Decline
33%
Design Outcomes
33%
Major Adverse Cardiovascular Events
33%
Cholesterol Reduction
33%
Multiple Risk Factors
33%
Short-term Change
33%
Randomized Clinical Trial
33%
Kidney Failure
33%
Heart Failure
33%
Response Variability
33%
Albumin-to-creatinine Ratio
28%
Protein-to-creatinine Ratio
25%
Kidney Disease
23%
Baat
22%
Kidney Failure Risk Equation
22%
Type 2 Diabetic Patients
20%
Left Ventricular Ejection Fraction
19%
Dipeptidyl peptidase-4 (DPP-4)
19%
Hazard Ratio
19%
Atherosclerotic Cardiovascular Disease (ASCVD)
19%
Hospitalization
19%
History of Heart Failure
19%
Risk Score
16%
Medicine and Dentistry
Cardiovascular System
87%
End Stage Renal Disease
75%
Drug Response
66%
Maturity Onset Diabetes of the Young
66%
Syndecan 1
66%
Linagliptin
66%
Hemodialysis
66%
Nephropathy
55%
Placebo
53%
Glomerular Filtration Rate
39%
Biological Marker
35%
Randomized Clinical Trial
33%
Exenatide
33%
Sodium Ion
33%
Drug Effect
33%
Risk Reduction
33%
Heart Failure
33%
Diabetic Nephropathy
33%
Renal Failure
30%
Patient with Type 2 Diabetes
28%
Hemoglobin A1c
25%
Creatinine
24%
Systolic Blood Pressure
22%
Body Mass Index
22%
Microalbuminuria
22%
Losartan
20%
Proportional Hazards Model
18%
Macroalbuminuria
15%
Dipeptidyl Peptidase-4 Inhibitor
14%
Hazard Ratio
14%
Personalized Medicine
13%
Cardiovascular Risk
12%
Heart Left Ventricle Ejection Fraction
12%
Relative Risk Reduction
11%
Chronic Kidney Disease
10%
Vascular Disease
10%
Diabetes
9%
Drug Therapy
8%
Angiotensin
6%
Glucagon Like Peptide 1
6%
Receptor
6%
Controlled Release
6%
Indapamide Plus Perindopril
6%
Clinical Decision Making
6%
Disease Exacerbation
6%
Gliclazide
6%
Glycocalyx
6%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
95%
End Stage Renal Disease
92%
Diabetic Nephropathy
71%
Kidney Failure
64%
Placebo
60%
Cardiovascular Risk
52%
Biological Marker
50%
Kidney Disease
40%
Creatinine
37%
Brain Natriuretic Peptide
33%
Exendin 4
33%
Dapagliflozin
33%
Linagliptin
33%
Aliskiren
33%
Heart Failure
33%
Randomized Clinical Trial
33%
Angiotensin
23%
Hemoglobin A1c
22%
Microalbuminuria
22%
Losartan
20%
Renin
16%
Aldosterone
16%
Clinical Trial
15%
Macroalbuminuria
15%
Vascular Disease
11%
Chronic Kidney Failure
11%
Therapy Resistance
11%
Cardiovascular Disease
11%
Albuminuria
9%
Dipeptidyl Peptidase IV Inhibitor
9%
Receptor
6%
Glucagon-Like Peptide-1
6%
Indapamide Plus Perindopril
6%
Gliclazide
6%
Disease Exacerbation
6%
Modified Release
6%
Hyperkalemia
5%
Acute Kidney Failure
5%
Symptom
5%
